Marketplace interviewed Partner Greg Husisian about the Foreign Investment Risk Review Modernization Act for the story “Congress Weighs Changes to Foreign Investment Oversight.” The legislation is intended to give the Committee on Foreign Investment in the United States new powers and more funding as the United States government grapples with how to best limit Chinese investment in critical technologies such as semiconductors and mobile broadband. The legislation would build on existing export controls and cover other types of deals such as joint ventures.
“That’s the part I find most fascinating. They’re looking at other situations,” Husisian said. “By requiring a kind of licensing scheme, they can potentially slow down or block the transfer of very important economic and national security type of information.”
“That’s the part I find most fascinating. They’re looking at other situations,” Husisian said. “By requiring a kind of licensing scheme, they can potentially slow down or block the transfer of very important economic and national security type of information.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”